Possible mechanism for in vitro complement activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation

Clinical Chemistry

Volumn 45, Issue 8 I, 1999, Pages 1190-1199

  Pfeifer, Philippe H ^a,b   Kawahara, Marleen S ^a   Hugli, Tony E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b BMA Biomedicals AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; EDETIC ACID; NAFAMSTAT MESILATE;

ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CENTRIFUGATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; LABORATORY DIAGNOSIS; LIVER TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032831351     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.8.1190     Document Type: Article

References (44)

1. Müller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem 1988;57:321-47.
2. Rother K, Rother U. Biological functions of the complement system. Prog Allergy 1986;39:24-100.
3. Hugli TE, Morgan EL. Mechanisms of leukocyte regulation by complement-derived factors. In: Snyderman R, ed. Contemporary topics in immunology, Vol. 14. New York: Plenum Publishing, 1984:109-53.
4. Hugli TE, Thoman ML, Weigle WO, Morgan EL. C5a-mediated enhancement of humoral and T-cell mediated immune responses [Abstract]. 15th International Leukocyte Culture Conference December 5-10, 1982, Asilomar, CA.
5. Fujii G, Selsted ME, Eisenberg MD. Defensins promote fusion and lysis of negatively charged membranes. Protein Sci 1993;2: 1301-12.
6. Morgan EL, Weigle WO, Hugli TE. Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses J Exp Med 1982; 155:1412-26.
7. Morgan EL. Complement fragment C5a and immunoregulation. Complement Today 1993;1:56-75.
8. Morgan EL, Thoman ML, Weigle WO, Hugli TE. Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses J Immunol 1983;130:1257-61.
9. Chenoweth DE, Goodman MG. The C5a receptor of neutrophils and macrophages. Agents Actions 1983;12:252-73.
10. Hugli TE, Müller-Eberhard HJ. Anaphylatoxins: C3a and C5a. In: Dixon FJ, Kunkel HG, eds. Advances in immunology, New York: Academic Press, 1978:1-53.
11. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 1995;92: 8955-9.
12. Moxley G, Ruddy S. Elevated plasma C3 anaphylatoxin levels in rheumatoid arthritis patients. Arthritis Rheum 1987;30:1097-104.
13. 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996;9:8563-8.
14. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
15. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995;5:1888-94.
16. Lange K, Wasserman E, Slobody LB. Significance of serum complement levels for diagnosis and prognosis of acute and subacute glomerulonephritis and lupus erythematosus disseminatus. Ann Intern Med 1960;53:636-46.
17. Stove S, Welte T, Wagner TOF, Kola A, Klos A, Bautsch W, et al. Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 1996;3:175-83.
18. Hack CE, Nuijens JH, Felt-Bersma RJF, Schreuder WO, Erenberg-Belmer AJM, Paardekooper J, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with fatal outcome in sepsis. Am J Med 1989;86:20-6.
19. Zilow G, Sturm JA, Rother U, Kirschfink M. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 1990;79:151-7.
20. Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA, et al. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Investig 1986;77: 1812-6.
21. Hecke F, Kola A, Bautsch W, Klos A, Kohl J. Circulating complement proteins in multiple trauma patients - correlation with injury severity, development of sepsis, and outcome. Crit Care Med 1997;25:2015-24.
22. Heideman M, Hugli TE. Anaphylatoxin generation in multisystem organ failure. J Trauma 1984;24:1038-43.
23. Dalmasso AP. The complement system in xenotransplantation. Immunopharmacology 1992;24:149-60.
24. Gewurz H, Clark DS, Cooper MD, Varco R, Good RA. Effect of cobra venom-factor induced inhibition of complement activity on allograft and Xenograft rejection reactions. Transplantation 1967;5:1296-303.
25. Kirschfink M, Wienert T, Rother K, Pomer S. Complement activation in renal allograft recipients. Transplantation Proc 1992;24: 2556-7.
26. Müller-Eberhard HJ. Complement. Ann Rev Biochem 1969;38: 389-414.
27. Otterness IG, Torchia AJ, Doshan HD. Complement inhibition by amidines and guanidines - in vivo and in vitro results. Biochem Pharmacol 1978;27:1873-8.
28. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981;661:342-5.
29. Hugli TE. Complement factors and inflammation: effects of alpha-thrombin on components C3 and C5. In: Lundblad RL, Fenton JW, Mann KG, eds. Chemistry and biology of thrombin, 1977 ed. Ann Arbor, MI: Ann Arbor Science, 1977:345-60.
30. Bokisch VA, Müller-Eberhard HJ, Cochrane CG. Isolation of a fragment (C3a) of the third component of complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 1969;129: 1109-30.
31. Ikari N, Sakai Y, Hitomi Y, Fujii S. New synthetic inhibitor to the alternative complement pathway. Immunology 1983;49:685-91.
32. Hitomi Y, Ikari N, Fujii S. Inhibitory effects of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985;15:164-8.
33. Hitomi Y, Fujii S. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol 1982;69:262-7.
34. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol 1986;41:155-62.
35. Watkins J, Wild G, Smith S. Nafamostat to stabilise plasma samples taken for complement measurements. Lancet 1989;1:896-7.
36. Reid KBM. C1q and mannose-binding lectin. In: Volanakis J, Frank M, eds. The human complement system in health and disease, New York: Marcel Dekker, 1998:33-48.
37. Ji YH, Fujita T, Hatsuse H, Takahashi A, Matsushita M, Kawakami M. Activation of the C4 and C2 components of complement by a proteinase in serum bactericidal factor, Ra reactive factor. J Immunol 1993;150:571-8.
38. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997; 386:506-10.
39. Pfeifer PH, Hugli TE, Davie EW, Fujikawa K. EDTA blood/plasma samples may be caused by coagulation proteases. In: Marshak DR, ed. Techniques in protein chemistry, Vol. VIII. San Diego: Academic Press, 1997:363-9.
40. Arlaud GJ, Colomb MG, Gagnon J. A functional model of the human CI complex. Immunol Today 1987;8:106-11.
41. Sim RB, Arlaud GJ, Colomb MG. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1 s. Biochem Biophys Acta 1980;612:433-49.
42. Pfeifer PH, Brems JJ, Brunson M, Collins D, Hugli TE. Measurement of complement C3a and C4a levels in liver transplant patients [Abstract]. The American Society of Transplant Surgeons 23rd Annual Scientific Meeting, May 14-16, 1997, Chicago, IL.
43. Bokisch VA, Müller-Eberhard HJ. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Investig 1970;49:2427-36.
44. Matsushita M, Takahashi M, Thiel S, Jensenius JC, Fujita T. Distinct proteolytic activities of MASP-1 and MASP-2 [Abstract]. Mol Immunol 1998;35:349.